C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · IEX Real-Time Price · USD
6.01
-0.03 (-0.41%)
Jul 22, 2024, 11:43 AM EDT - Market open
C4 Therapeutics Employees
C4 Therapeutics had 145 employees as of December 31, 2023. The number of employees decreased by 1 or -0.68% compared to the previous year.
Employees
145
Change (1Y)
-1
Growth (1Y)
-0.68%
Revenue / Employee
$138,179
Profits / Employee
-$869,476
Market Cap
408.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 145 | -1 | -0.68% |
Dec 31, 2022 | 146 | 25 | 20.66% |
Dec 31, 2021 | 121 | 22 | 22.22% |
Dec 31, 2020 | 99 | 11 | 12.50% |
Dec 31, 2019 | 88 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Sonida Senior Living | 3,955 |
Health Catalyst | 1,300 |
Cerus | 637 |
Anika Therapeutics | 357 |
Editas Medicine | 265 |
Esperion Therapeutics | 240 |
Korro Bio | 102 |
Aura Biosciences | 89 |
CCCC News
- 5 days ago - C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 - GlobeNewsWire
- 14 days ago - C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day - GlobeNewsWire
- 6 weeks ago - C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors - GlobeNewsWire
- 2 months ago - C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum - GlobeNewsWire
- 3 months ago - C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 4 months ago - C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire